Introduction {#Sec1}
============

The aim of the present study was to cross-culturally adapt and validate the Polish parent, child/adult version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) \[[@CR1]\] in patients with juvenile idiopathic arthritis (JIA). The JAMAR assesses the most relevant parent/patient-reported outcomes in JIA, including overall well-being, functional status, health-related quality of life (HRQoL), pain, morning stiffness, disease activity/status/course, articular and extra-articular involvement, drug-related side effects/compliance and satisfaction with illness outcome.

This project was part of a larger multinational study conducted by the Paediatric Rheumatology International Trials Organisation (PRINTO) \[[@CR2]\] aimed to evaluate the Epidemiology, Outcome and Treatment of Childhood Arthritis (EPOCA) in different geographic areas \[[@CR3]\].

We report herein the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Polish language.

Materials and methods {#Sec2}
=====================

The methodology employed has been described in detail in the introductory paper of the supplement \[[@CR4]\]. In brief, it was a cross-sectional study of JIA children, classified according to the ILAR criteria \[[@CR5], [@CR6]\] enrolled from March 2012 to September 2013. Children were recruited after Ethics Committee approval and consent from at least one parent.

The JAMAR {#Sec3}
---------

The JAMAR \[[@CR1]\] includes the following 15 sections:

assessment of physical function (PF) using 15 items in which the ability of the child to perform each task is scored as follows: 0 = without difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do and not applicable if it was not possible to answer the question or the patient was unable to perform the task due to their young age or to reasons other than JIA. The total PF score ranges from 0 to 45 and has 3 components: PF-lower limbs (PF-LL); PF-hand and wrist (PF-HW) and PF-upper segment (PF-US) each scoring from 0 to 15 \[[@CR7]\]. Higher scores indicating higher degree of disability \[[@CR8]--[@CR10]\];rating of the intensity of the patient's pain on a 21-numbered circle Visual Analogue Scale (VAS) \[[@CR11]\];assessment of the presence of joint pain or swelling (present/absent for each joint);assessment of morning stiffness (present/absent);assessment of extra-articular symptoms (fever and rash) (present/absent);rating of the level of disease activity on a 21-circle VAS;rating of disease status at the time of the visit (categorical scale);rating of disease course from previous visit (categorical scale);checklist of the medications the patient is taking (list of choices);checklist of side effects of medications;report of difficulties with medication administration (list of items);report of school/university/work problems caused by the disease (list of items);assessment of HRQoL, through the physical health (PhH), and psychosocial health (PsH) subscales (5 items each) and a total score. The four-point Likert response, referring to the prior month, are 'never' (score = 0), 'sometimes' (score = 1), 'most of the time' (score = 2) and 'all the time' (score = 3). A 'not assessable' column was included in the parent version of the questionnaire to designate questions that cannot be answered because of developmental immaturity. The total HRQoL score ranges from 0 to 30, with higher scores indicating worse HRQoL. A separate score for PhH and PsH (range 0--15) can be calculated \[[@CR12]--[@CR14]\];rating of the patient's overall well-being on a 21-numbered circle VAS;a question about satisfaction with the outcome of the illness (Yes/No) \[[@CR15]\].

The JAMAR is available in two versions, one for parent proxy-report (child's age 2--18), one for child self-report, with the suggested age range of 7--18 years, and one for adults.

Cross-cultural adaptation and validation {#Sec4}
----------------------------------------

The process of cross-cultural adaptation was conducted according to international guidelines with 2--3 forward and backward translations. In those countries for which the translation of JAMAR had been already cross-cultural adapted in a similar language (i.e. Spanish in South American countries), only the probe technique was performed. Reading comprehension and understanding of the translated questionnaires were tested in a probe sample of 10 JIA parents and 10 patients.

Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents.

The statistical validation phase explored the descriptive statistics and the psychometric issues \[[@CR16]\]. In particular, we evaluated the following validity components: the first Likert assumption \[mean and standard deviation (SD) equivalence\]; the second Likert assumption or equal item--scale correlations (Pearson *r*: all items within a scale should contribute equally to the total score); third Likert assumption (item internal consistency or linearity for which each item of a scale should be linearly related to the total score that is 90% of the items should have Pearson *r* ≥ 0.4); floor/ceiling effects (frequency of items at lower and higher extremes of the scales, respectively); internal consistency, measured by the Cronbach's alpha, interscale correlation (the correlation between two scales should be lower than their reliability coefficients, as measured by Cronbach's alpha); test--retest reliability or intra-class correlation coefficient (reproducibility of the JAMAR repeated after 1 or 2 weeks); and construct validity in its two components: the convergent or external validity which examines the correlation of the JAMAR subscales with the 6 JIA core set variables, with the addition of the parent assessment of disease activity and pain by the Spearman's correlation coefficients (*r*) \[[@CR17]\] and the discriminant validity, which assesses whether the JAMAR discriminates between the different JIA categories and healthy children \[[@CR18]\].

Quantitative data were reported as medians with 1st and 3rd quartiles and categorical data as absolute frequencies and percentages.

The complete Polish parent and patient versions of the JAMAR are available upon request to PRINTO.

Results {#Sec5}
=======

Cross-cultural adaptation {#Sec6}
-------------------------

The Polish JAMAR was fully cross-culturally adapted from the standard English version with 3 forward and 2 backward translations with a concordance for 118/123 translations lines (96%) for the parent version and 116/120 lines (97%) for the child version.

The 123 lines were understood by 10/10 of the parents (median = 100%; range: 100--100%). The 120 lines of the child version were understood by 10/10 (median = 100%; range: 100--100%). The text of the parent JAMAR was unmodified after the probe technique.

The text of the parent JAMAR was unmodified after the probe technique.

Demographic and clinical characteristics of the subjects {#Sec7}
--------------------------------------------------------

A total of 156 JIA patients and 92 healthy children (total of 248 subjects), were enrolled at two paediatric rheumatology centres. Two JIA patients and one healthy child did not give the consent to use their data.

In the 154 JIA subjects, the JIA categories were 10.4% with systemic arthritis, 50.0% with oligoarthritis, 24.7% with RF-negative polyarthritis, 5.8% with RF-positive polyarthritis, 5.2% with enthesitis-related arthritis and 3.9% with undifferentiated arthritis. Notably, none of the enrolled JIA patients is affected with psoriatic arthritis (Table [1](#Tab1){ref-type="table"}).

Table 1Descriptive statistics (medians, 1st 3rd quartiles or absolute frequencies and %) for the 154 JIA patientsSystemicOligoarthritisRF− Poly-arthritisRF+ Poly-arthritisEnthesitis-related arthritisUndifferentiated arthritisAll JIA patientsHealthy*N* = 16*N* = 77*N* = 38*N* = 9*N* = 8*N* = 6*N* = 154*N* = 91Female8 (50%)59 (76.6%)29 (76.3%)9 (100%)3 (37.5%)5 (83.3%)113 (73.4%)45 (49.5%)^\*\*^Age at visit11.3 (9.3--14.2)11.8 (9--14)13.3 (9.8--15.5)15.7 (15.4--16.1)13.7 (11.6--16.1)15.9 (9.3--17)12.4 (9.5--15.4)\*10.7 (9.1--14)\*Age at onset5.1 (2.6--8.5)6.8 (4.1--9.3)7.2 (4.6--10.1)12.9 (11-13.9)11.9 (8.6--14.5)11.2 (6.4--11.3)7 (4.5--10.8)\*\*Disease duration6 (1.6--7.7)3.4 (1.3--6.9)4.1 (1.8--7.7)2.9 (1.3--3.8)1.6 (1--1.9)3.9 (3.4--4.5)3.5 (1.4--6.7)ESR9 (3--11)8 (5--13)10 (6--17)16 (8--37)10 (8--12.5)17.5 (6--67)9 (6--15)MD VAS0 (0--2)3 (1--5)4 (1--6)7 (1--9)4 (4--4)2.5 (0--5)3 (1--5)\*No. swollen joints0 (0--1)1 (0--2)2 (0--4)2 (0--7)1.5 (1--3)1 (0--2)1 (0--2)\*No. joints with pain0 (0--1)0 (0--1)0 (0--4)2 (0--8)1 (0.5-2)0.5 (0--2)0 (0--2)No. joints with LOM0 (0--2)1 (0--2)2.5 (1--9)4 (0--8)1 (0.5--1.5)0 (0--2)1 (0--2)\*No. active joints0 (0--1)1 (0--2)2 (0--6)2 (0--8)1.5 (1--3)1 (0--2)1 (0--2)\*Active systemic features1 (6.3%)0 (0%)0 (0%)1 (11.1%)0 (0%)0 (0%)2/148 (1.4%)ANA status2 (12.5%)25 (32.5%)9 (23.7%)4 (44.4%)0 (0%)1 (16.7%)41 (26.6%)Uveitis0 (0%)12 (15.6%)2/36 (5.6%)0 (0%)1 (12.5%)0 (0%)15/152 (9.9%)PF Total Score0 (0--2)1 (0--4)3 (1--8)3 (2--7)2.5 (1.5--6.5)0 (0--4)2 (0--5)\*0 (0--0)^**\#**^Pain VAS0.5 (0--3)1 (0--4)3 (0.5--5)1 (0.5--5)2.5 (1--4.3)1.5 (0--2)1.3 (0--4.3)0 (0--0)^**\#**^Disease Activity VAS1 (0--3)2.5 (0.5--5)3.5 (0.5--6.3)1.5 (1--6.5)3 (1.5--5)4.8 (1-8.3)2.5 (0.5--6)Well-being VAS2 (0--5)1.5 (0--4)3.5 (1--5.5)1 (0.3--6.5)3 (1--4.3)1 (1--4)2 (0.5--5)HRQoL-PhH2 (0.5-6)2 (1--5)4 (1--7)4.5 (2.5--7)3 (2--7)2 (0--4)3 (1--6)0 (0--0)^**\#**^HRQoL-PsH4.5 (1-54.5)3 (1--5)4 (3--4)2.5 (0.5--5)3.5 (2.5--5)1 (0--2)3 (1--5)0 (0--3)^**\#**^HRQoL total Score7.5 (3--58)6 (2--10)7 (5--13)8.5 (3--11)7.5 (4--10.5)3 (0--6)7 (3--10)0 (0--3)^**\#**^Pain/swell. in \> 1 joint5 (31.3%)52 (67.5%)28 (73.7%)6 (66.7%)7 (87.5%)3/5 (60%)101/153 (66%)5/90 (5.6%)^**\#**^Morning stiffness \> 15 min2 (12.5%)12/75 (16%)10 (26.3%)3 (33.3%)3 (37.5%)1/5 (20%)31/151 (20.5%)1/90 (1.1%)^**\#**^Subjective remission4/14 (28.6%)48/75 (64%)27 (71.1%)7 (77.8%)7 (87.5%)3/5 (60%)96/149 (64.4%)\*In treatment15 (93.8%)73 (94.8%)37 (97.4%)9 (100%)8 (100%)5/5 (100%)147/153 (96.1%)Reporting side effects6/15 (40%)23/70 (32.9%)9/35 (25.7%)3 (33.3%)8 (100%)0 (0%)49/142 (34.5%)Taking medication regularly15/15 (100%)66/71 (93%)35/36 (97.2%)8 (88.9%)6 (75%)5/5 (100%)135/144 (93.8%)With problems attending school1/6 (16.7%)11/38 (28.9%)8/21 (38.1%)3/6 (50%)1/7 (14.3%)0 (0%)24/82 (29.3%)1 (1.1%)^**\#**^Satisfied with disease outcome15 (93.8%)62 (80.5%)28/36 (77.8%)7 (77.8%)5 (62.5%)5/5 (100%)122/151 (80.8%)Data related to the JAMAR refers to the 153 JIA patients and to the 90 healthy subjects for whom the questionnaire has been completed by the parents*JAMAR* Juvenile Arthritis Multidimensional Assessment Report, *ESR* erythrocyte sedimentation rate, *MD* medical doctor, *VAS* Visual Analogue Scale (score 0--10; 0 = no activity, 10 = maximum activity), *LOM* limitation of motion, *ANA* anti-nuclear antibodies, *PF* physical function (total score ranges from 0 to 45), *HRQoL* health-related quality of life (total score ranges from 0 to 30), *PhH* physical health (total score ranges from 0 to 15), *PsH* psychosocial health (total score ranges from 0 to 15)*p* values refer to the comparison of the different JIA categories or to JIA versus healthy. \**p* \< 0.05, \*\**p* \< 0.001, ^**\#**^*p* \< 0.0001

A total of 243/245 (99.2%) subjects had the parent version of the JAMAR completed by a parent (153 from parents of JIA patients and 90 from parents of healthy children). The JAMAR was completed by 210/243 (86.4%) mothers and 33/243 (13.6%) fathers. The child version of the JAMAR was completed by 208/245 (84.9%) children aged 5.8 or older. Also patients younger than 7 years, capable to assess their personal condition and able to read and write, were asked to fill in the patient version of the questionnaire.

Discriminant validity {#Sec8}
---------------------

The JAMAR results are presented in Table [1](#Tab1){ref-type="table"}, including the scores \[median (1st--3rd quartile)\] obtained for the PF, the PhH, the PsH subscales and total score of the HRQoL scales. The JAMAR components discriminated well between healthy subjects and JIA patients.

In summary, the JAMAR revealed that JIA patients had a greater level of disability and pain, as well as a lower HRQoL than their healthy peers.

Psychometric issues {#Sec9}
-------------------

The main psychometric properties of both parent and child versions of the JAMAR are reported in Table [2](#Tab2){ref-type="table"}. The following \"[Results](#Sec5){ref-type="sec"}\" section refers mainly to the parent's version findings, unless otherwise specified.

Table 2Main psychometric characteristics between the parent and child version of the JAMARParent *N* = 153/243Child *N* = 129/208Missing values (1st--3rd quartiles)2.0 (0.7--2.6)1.6 (0.8--2.3)Response patternPF and HRQoL positively skewedPF and HRQoL positively skewedFloor effect, median PF81.0%82.9% HRQoL-PhH47.7%50.4% HRQoL-PsH40.5%55.0% Pain VAS28.8%27.9% Disease activity VAS20.3%25.6% Well-being VAS22.2%21.7%Ceiling effect, median PF0.0%0.8% HRQoL-PhH3.3%3.9% HRQoL-PsH2.0%1.6% Pain VAS0.6%0.8% Disease activity VAS1.3%0.8% Well-being VAS2.0%3.1%Items with equivalent item--scale correlation87% for PF, 100% for HRQoL100% for PF, 100% for HRQoLItems with item--scale correlation ≥ 0.487% for PF, 100% for HRQoL100% for PF, 100% for HRQoLCronbach's alpha PF-LL0.910.90 PF-HW0.890.91 PF-US0.740.91 HRQoL-PhH0.890.89 HRQoL-PsH0.810.81Items with item--scale correlation lower than the Cronbach's alpha100% for PF, 100% for HRQoL100% for PF, 100% for HRQoLTest--retest intraclass correlation PF total score0.000.29 HRQoL-PhH0.880.95 HRQoL-PsH0.640.93Spearman's correlation with JIA core set variables, median PF0.50.5 HRQoL-PhH0.40.4 HRQoL-PsH0.20.3 Pain VAS0.30.3 Disease activity VAS0.30.2 Well-being VAS0.30.3*JAMAR* Juvenile Arthritis Multidimensional Assessment Report, *JIA* juvenile idiopathic arthritis, *VAS* Visual Analogue Scale, *PF* physical function, *HRQoL* health-related quality of life, *PhH* physical health, *PsH* psychosocial health, *PF-LL* PF-lower limbs, *PF-HW* PF-hand and wrist, *PF-US* PF-upper segment

Descriptive statistics (first Likert assumption) {#Sec10}
------------------------------------------------

For all the JAMAR items the median number of missing responses was 2.0 (0.7--2.6).

The response pattern for both PF and HRQoL was positively skewed toward normal functional ability and normal HRQoL. All response choices were used for the different HRQoL items except for item 8, whereas a reduced number of response choices was used for PF items 2, 6, 8, 9, 11, 12, 13, 14 and 15.

The mean and SD of the items within a scale were roughly equivalent for the PF and for the HRQoL items (data not shown). The median number of items marked as not applicable was 3% (2--3%) for the PF and 6.5% (5--10%) for the HRQoL.

Floor and ceiling effect {#Sec11}
------------------------

The median floor effect was 81.0% (69.9--88.9%) for the PF items, 47.7% (34.6--54.9%) for the HRQoL-PhH items, and 40.5% (37.3--44.4%) for the HRQoL-PsH items. The median ceiling effect was 0% (0--1.3%) for the PF items, 3.3% (3.3--7.8%) for the HRQoL-PhH items, and 2.0% (1.3--2.0%) for the HRQoL-PsH items. The median floor effect was 28.8% for the pain VAS, 20.3% for the disease activity VAS and 22.2% for the well-being VAS. The median ceiling effect was 0.6% for the pain VAS, 1.3% for the disease activity VAS and 2.0% for the well-being VAS.

Equal item--scale correlations (second Likert assumption) {#Sec12}
---------------------------------------------------------

Pearson's item--scale correlations corrected for overlap were roughly equivalent for items within a scale for 87% of the PF items, with the exception of PF items 11 and 15, and for 100% of the HRQoL items.

Items internal consistency (third Likert assumption) {#Sec13}
----------------------------------------------------

Pearson's item--scale correlations were ≥ 0.4 for 87% of items of the PF (except for PF items 11 and 15) and 100% of items of the HRQoL.

Cronbach's alpha internal consistency {#Sec14}
-------------------------------------

Cronbach's alpha was 0.91 for PF-LL, 0.89 for PF-HW, 0.74 for PF-US. Cronbach's alpha was 0.89 for HRQoL-PhH and 0.81 for HRQoL-PsH.

Interscale correlation {#Sec15}
----------------------

The Pearson's correlation of each item of the PF and the HRQoL with all items included in the remaining scales of the questionnaires was lower than the Cronbach's alpha.

Test--retest reliability {#Sec16}
------------------------

Reliability was assessed in 10 JIA patients, by re-administering both versions (parent and child) of the JAMAR after a median of 6 days (6--6 days). The intraclass correlation coefficients (ICC) for the PF total score showed a poor reproducibility (ICC = 0.0). The ICC for the HRQoL-PhH showed an almost perfect reproducibility (ICC = 0.88) while the ICC for the HRQoL-PsH showed a substantial reproducibility (ICC = 0.64).

Convergent validity {#Sec17}
-------------------

The Spearman's correlation of the PF total score with the JIA core set of outcome variables ranged from 0.4 to 0.5 (median = 0.5). The PF total score best correlation was observed with the parent's assessment of pain (*r* = 0.6, *p* \< 0.001). For the HRQoL, the median correlation of the PhH with the JIA core set of outcome variables ranged from 0.3 to 0.6 (median = 0.4), whereas for the PsH ranged from 0.1 to 0.5 (median = 0.2). The PhH showed the best correlation with the parent's assessment of pain (*r* = 0.7, *p* \< 0.001) and the PsH with the parent global assessment of well-being (*r* = 0.5, *p* \< 0.001). The median correlations between the pain VAS, the well-being VAS, and the disease activity VAS and the physician-centred and laboratory measures were 0.3 (0.2--0.5), 0.3 (0.2--0.4), 0.3 (0.3--0.5), respectively.

Discussion {#Sec18}
==========

In this study, the Polish version of the JAMAR was cross-culturally adapted from the original standard English version with 3 forward and 2 backward translations. According to the results of the validation analysis, the Polish parent and patient versions of the JAMAR possess satisfactory psychometric properties. The disease-specific components of the questionnaire discriminated well between patients with JIA and healthy controls. The PF total score proved to discriminate between the different JIA subtypes with children with RF− and RF + poly-arthritis having a higher degree of disability.

Psychometric performances were good for all domains of the JAMAR with few exceptions: 2 PF items (stretch arms and bite a sandwich or an apple) showed a lower item's internal consistency. However, the overall internal consistency was excellent for all the domains.

In the external validity evaluation, the Spearman's correlations of the PF and HRQoL scores with JIA core set parameters ranged from weak to moderate.

The results obtained for the parent version of the JAMAR are very similar to those obtained for the child version, which suggests that children are equally reliable proxy reporters of their disease and health status as their parents. The JAMAR is aimed to evaluate the side effects of medications and school attendance, which are other dimensions of daily life that were not previously considered by other HRQoL tools. This may provide useful information for intervention and follow-up in health care.

In conclusion, the Polish version of the JAMAR was found to have satisfactory psychometric properties and it is, thus, a reliable and valid tool for the multidimensional assessment of children with JIA.
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